Drugs / EN-374
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06876363 | Aug 2025 → Dec 2027 expected | granulomatous disease, chronic, X-linked | Ensoma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-08 | Ensoma | Results Ensoma to Present Clinical Safety Data from First Participant Dosed with In Vivo HSC Engineering Therapy at ASGCT Annual Meeting ensoma.com ↗
We are excited to discuss encouraging initial safety data from the first participant in our Phase 1/2 clinical trial of EN-374 for X-CGD, the first-ever in vivo HSC gene insertion therapy in the clinic. |
| 2025-12-10 | Ensoma | Regulatory Ensoma Announces Clearance of U.K. Clinical Trial Authorization Application for EN-374, First In Vivo HSC-Directed Gene Insertion Therapy ensoma.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EN-374 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06876363 ↗ |
| Action | Restore | “express a wild-type CYBB gene” NCT06876363 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT06876363 ↗ |
| Target | CYBB | “to genetically modify hematopoietic stem cells (HSCs) to express a wild-type CYBB gene” NCT06876363 ↗ |